Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review - Summary - MDSpire

Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review

  • By

  • Anna M. Dornisch

  • Allison Y. Zhong

  • Darren M. C. Poon

  • Alison C. Tree

  • Tyler M. Seibert

  • January 20, 2024

  • 0 min

Share

Objective:

To synthesize evidence supporting MR-guided focal boost to intraprostatic lesions (IPLs) and discuss specific barriers to implementation, such as clinical, logistical, and technological challenges.

Key Findings:
  • The synthesized biochemical disease-free survival (bDFS) was 92.4% for studies with follow-up greater than 5 years, indicating a strong potential for long-term efficacy.
  • Focal RT boost improved bDFS without increased toxicity or decreased quality of life, suggesting a favorable risk-benefit profile.
  • Seven prospective phase II/III trials involving 723 patients were included in the review, highlighting the robustness of the evidence base.
Interpretation:

MR-guided focal boost to IPLs shows promise in enhancing treatment efficacy while minimizing toxicity, supporting its clinical application.

Limitations:
  • Limited number of studies included in the review, which may affect the generalizability of the findings.
  • Variability in study designs and patient populations, which could introduce bias and limit comparability.
Conclusion:

The evidence supports the efficacy of MR-guided focal boosts in prostate cancer treatment, but further research is needed to address implementation barriers, particularly in clinical practice and technology integration.

Original Source(s)

Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review

  • by Anna M. Dornisch, Allison Y. Zhong, Darren M. C. Poon, Alison C. Tree, Tyler M. Seibert

  • January 20, 2024

Related Content

Dana-Farber Research News 03.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.

  • by

  • March 15, 2026

  • 21 min
Precision Oncology in Practice: How Theranostics Personalizes Treatment

In precision oncology, theranostics stands out as a transformative approach that tailors cancer treatment to the unique molecular profile of each patient. By integrating advanced diagnostic imaging with targeted therapy, theranostics ensures that treatments are customized to the unique characteristics of each patient's cancer, thereby optimizing efficacy and minimizing adverse effects.

  • by

  • May 11, 2025

  • 4 min
Evaluating the Role of PSMA-PET in Enhancing Salvage Radiotherapy: A Discussion on Precision versus Timing